Cargando…

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Targeting MAPK pathway in mutant BRAF melanoma with the specific BRAF inhibitor vemurafenib showed robust initial responses in the majority of patients followed by relapses due to acquired resistance to the drug. In (V600E)BRAF melanoma cell lines, senescence-associated β-galactosidase activity is o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krayem, Mohammad, Najem, Ahmad, Journe, Fabrice, Morandini, Renato, Sales, François, Awada, Ahmad, Ghanem, Ghanem E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112757/ https://www.ncbi.nlm.nih.gov/pubmed/30159130 http://dx.doi.org/10.18632/oncotarget.25879

Ejemplares similares

RTK Inhibitors in Melanoma: From Bench to Bedside
por: Sabbah, Malak, et al.
Publicado: (2021)

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
por: Sabbah, Malak, et al.
Publicado: (2023)

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma
por: Najem, Ahmad, et al.
Publicado: (2022)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies
por: Najem, Ahmad, et al.
Publicado: (2023)

The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma
por: Krayem, Mohammad, et al.
Publicado: (2019)

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value
por: Najem, Ahmad, et al.
Publicado: (2021)

Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
por: Soumoy, Laura, et al.
Publicado: (2020)

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
por: Kehagias, Pashalina, et al.
Publicado: (2022)

Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
por: Krayem, Mohamad, et al.
Publicado: (2020)

Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms
por: Soumoy, Laura, et al.
Publicado: (2020)

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512
por: Krayem, Mohammad, et al.
Publicado: (2020)

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
por: Thompson, Elizabeth L., et al.
Publicado: (2021)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Cytokine Landscape in Central Nervous System Metastases
por: Marin, Julie, et al.
Publicado: (2022)

Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma
por: Soumoy, Laura, et al.
Publicado: (2019)

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
por: Prasad, Chandra Prakash, et al.
Publicado: (2015)

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
por: Reddi, Kiran Kumar, et al.
Publicado: (2022)

Harnessing host innate immunity may combat acquired resistance to BRAFi
por: Tan, Thomas, et al.
Publicado: (2014)

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
por: de Bakker, Tycho, et al.
Publicado: (2022)

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research
por: Cogels, Morgane M., et al.
Publicado: (2021)

BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma
por: Gebhardt, Kathleen, et al.
Publicado: (2021)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
por: Paris, Anaïs, et al.
Publicado: (2022)

Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas
por: Kindt, Nadège, et al.
Publicado: (2017)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome
por: Journe, F, et al.
Publicado: (2011)

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
por: Stark, Mitchell S., et al.
Publicado: (2015)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells
por: Franco, Ylana Adami, et al.
Publicado: (2023)

Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients
por: El Hajj, P, et al.
Publicado: (2013)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

A game-theoretic approach to assess peer-to-peer rooftop solar PV electricity trading under constrained power supply
por: Krayem, Alaa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5n82vsrdj0hb83v8tod3eosng3